1. Pink Sheet
  2. >>Geography
  3. >>Europe

EMA Explains Process For Assessing Suitability Of Biomarkers With Concerned Medicines

 
• By Vibha Sharma

A new EU guideline outlines the steps that notified bodies can take to facilitate the European Medicines Agency’s assessment of the appropriateness of a companion diagnostic’s use with a drug.

Liquid Biopsy Technology Concept - Early Detection of Cancer Through Circulating DNA Mutations - Innovative Cancer Screening Technology - Innovation in Oncology - 3D Illustration
IVD Regulation makes it mandatory for companion diagnostics to undergo a conformity assessment by a notified body • Source: Shutterstock

The European Medicines Agency has issued final guidance outlining the procedure that notified bodies designated to review in vitro diagnostics (IVDs) must follow when seeking a scientific opinion on the suitability of a companion diagnostic (CDx) with the concerned medicinal product.

The guideline is expected to further support the development of CDxs or biomarkers that are a critical tool for furthering...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

ACIP Upheaval Leaves Merck & Co. In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.